<DOC>
	<DOC>NCT02914457</DOC>
	<brief_summary>The SYNSEQ study intends to assess the positive left ventricular dP/dt max achieved by multipoint LV pacing (either simultaneously or sequentially) in comparison to the response achieved by the current (standard) BiV pacing configuration in patients indicated/recommended for cardiac resynchronization therapy.</brief_summary>
	<brief_title>Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject is indicated or recommended for CRTP or CRTD device according to current applicable ESC/AHA guidelines Subject is in sinus rhythm Subject receives optimal heart failure oral medical therapy Subject is willing to sign the informed consent form Subject is 18 years or older Subject has permanent atrial fibrillation/flutter or tachycardia Subject has pure right bundle branch block (= no additional left ventricular conduction delays) Subject has left bundle branch block and QRSduration of &gt; 150 ms and no sign of myocardial scar indicated by late gadolinium enhancement MRI Subject experienced recent myocardial infarction, within 40 days prior to enrollment Subject underwent valve surgery, within 90 days prior to enrollment Subject is post heart transplantation, or is actively listed on the transplantation list Subject is implanted with a left ventricular assist device Subject has severe renal disease (up to physicians discretion) Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure (â‰¥ 2 stable infusions per week) Subject has severe aortic stenosis (with a valve area of &lt;1.0 cm2 or significant valve disease expected to be operated within study period) Subject has complex and uncorrected congenital heart disease Subject has a mechanical heart valve Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control Subject is enrolled in another study that could confound the results of this study, without documented preapproval from Medtronic study manager</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>